BR112013031539A2 - agentes terapêuticos para regular fósforo sérico - Google Patents

agentes terapêuticos para regular fósforo sérico Download PDF

Info

Publication number
BR112013031539A2
BR112013031539A2 BR112013031539A BR112013031539A BR112013031539A2 BR 112013031539 A2 BR112013031539 A2 BR 112013031539A2 BR 112013031539 A BR112013031539 A BR 112013031539A BR 112013031539 A BR112013031539 A BR 112013031539A BR 112013031539 A2 BR112013031539 A2 BR 112013031539A2
Authority
BR
Brazil
Prior art keywords
seq
hemodialysis
hours
dialysis
compound
Prior art date
Application number
BR112013031539A
Other languages
English (en)
Portuguese (pt)
Inventor
Karim Felix
Bell Gregory
Original Assignee
Kai Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kai Pharmaceuticals Inc filed Critical Kai Pharmaceuticals Inc
Publication of BR112013031539A2 publication Critical patent/BR112013031539A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
BR112013031539A 2011-06-08 2012-06-08 agentes terapêuticos para regular fósforo sérico BR112013031539A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161494874P 2011-06-08 2011-06-08
PCT/US2012/041759 WO2012170955A1 (en) 2011-06-08 2012-06-08 Therapeutic agents for regulating serum phosphorus

Publications (1)

Publication Number Publication Date
BR112013031539A2 true BR112013031539A2 (pt) 2019-07-30

Family

ID=46321485

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013031539A BR112013031539A2 (pt) 2011-06-08 2012-06-08 agentes terapêuticos para regular fósforo sérico

Country Status (23)

Country Link
US (1) US8969299B2 (cg-RX-API-DMAC7.html)
EP (1) EP2717896B1 (cg-RX-API-DMAC7.html)
JP (1) JP5982473B2 (cg-RX-API-DMAC7.html)
KR (1) KR102057508B1 (cg-RX-API-DMAC7.html)
CN (1) CN103857405B (cg-RX-API-DMAC7.html)
AU (1) AU2012267470C1 (cg-RX-API-DMAC7.html)
BR (1) BR112013031539A2 (cg-RX-API-DMAC7.html)
CA (1) CA2837445C (cg-RX-API-DMAC7.html)
CY (1) CY1118430T1 (cg-RX-API-DMAC7.html)
DK (1) DK2717896T3 (cg-RX-API-DMAC7.html)
ES (1) ES2607986T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20161566T1 (cg-RX-API-DMAC7.html)
HU (1) HUE032087T2 (cg-RX-API-DMAC7.html)
LT (1) LT2717896T (cg-RX-API-DMAC7.html)
MX (1) MX337613B (cg-RX-API-DMAC7.html)
PL (1) PL2717896T3 (cg-RX-API-DMAC7.html)
PT (1) PT2717896T (cg-RX-API-DMAC7.html)
RS (1) RS55503B1 (cg-RX-API-DMAC7.html)
RU (1) RU2612912C2 (cg-RX-API-DMAC7.html)
SG (1) SG195290A1 (cg-RX-API-DMAC7.html)
SI (1) SI2717896T1 (cg-RX-API-DMAC7.html)
SM (2) SMT201700081T1 (cg-RX-API-DMAC7.html)
WO (1) WO2012170955A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2459208B1 (en) * 2009-07-29 2016-09-28 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
PE20160549A1 (es) * 2013-06-28 2016-06-15 Amgen Inc Formulacion liquida estable de etelcalcetida (amg 416)
RU2686086C1 (ru) * 2018-05-17 2019-04-24 федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ коррекции пресаркопении или саркопении у пациента с адекватным потреблением основных нутриентов, получающего лечение программным гемодиализом
WO2021115272A1 (zh) * 2019-12-09 2021-06-17 北京拓界生物医药科技有限公司 钙敏感受体激动剂化合物及其应用
KR20230066044A (ko) * 2020-09-10 2023-05-12 샨시 마이콧 테크놀로지 컴퍼니 리미티드 이중특이적 융합 폴리펩타이드 화합물

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602116A (en) 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5869473A (en) 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
AU9131091A (en) 1990-11-07 1992-06-11 Scripps Research Institute, The Peptides that inhibit platelet binding of adhesion molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
WO1995006056A1 (en) 1993-08-20 1995-03-02 University Of Medicine & Dentistry Of New Jersey Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same
CA2145214A1 (en) 1995-02-28 1996-08-29 Rick E. Preddie Agents for pre-symptomatic diagnosis, prevention and cure huntington's disease (hd) in humans
US5688489A (en) 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US5895368A (en) * 1996-09-23 1999-04-20 Medisystems Technology Corporation Blood set priming method and apparatus
US6165977A (en) 1996-10-18 2000-12-26 Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase C methods and compositions
US6258774B1 (en) 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
JP2000336099A (ja) 1999-05-27 2000-12-05 Sekisui Chem Co Ltd ペプチド及びc型肝炎抗体検出用試薬
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
US6051567A (en) 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
JP2004504295A (ja) 2000-07-18 2004-02-12 ボーン ケア インターナショナル インコーポレイテッド 安定化1α−ヒドロキシビタミンD
US20080249016A1 (en) 2000-09-18 2008-10-09 Sanos Bioscience A/S Use of GLP-2 in a combination treatment for bone-related disorders
US20020168354A1 (en) 2000-11-10 2002-11-14 Daria Mochly-Rosen psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia
CA2434643C (en) 2001-01-18 2013-10-29 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of.delta.pkc
AU2002240312A1 (en) 2001-02-08 2002-08-19 Pankaj Paranjp Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates
US20030036627A1 (en) 2001-02-16 2003-02-20 Montelaro Ronald C. Virus derived antimicrobial peptides
US7253146B2 (en) 2001-02-23 2007-08-07 Polyphor Ltd Template-fixed peptidomimetics with antimicrobial activity
JP2005287302A (ja) 2002-04-03 2005-10-20 Haruhiko Fujiwara ポリペプチドの架橋方法
AU2003299496A1 (en) 2002-05-14 2004-05-25 Bristol-Myers Squibb Company Polynucleotide encoding novel human g-protein coupled receptors, and splice variants thereof
WO2004093821A2 (en) 2003-04-22 2004-11-04 Hawaii Biotech, Inc. Treatment of anthrax infection using inhibitors of lethal factor protease activity
CA2543072A1 (en) 2003-11-05 2005-06-02 Pevion Biotech Ltd. Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens
US20050187156A1 (en) 2003-12-11 2005-08-25 Daria Mochly-Rosen Isozyme-specific antagonists of protein kinase C
US7939634B2 (en) 2004-01-27 2011-05-10 Compugen Ltd. Polynucleotides encoding polypeptides and methods using same
US7265092B2 (en) 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
ITME20040015A1 (it) * 2004-12-07 2005-03-07 Vincenzo Savica Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
US20070066514A1 (en) 2005-08-30 2007-03-22 Acologix, Inc. Regulation of mineral and skeletal metabolism
WO2007038172A2 (en) 2005-09-23 2007-04-05 Nitto Denko Corporation Guanidinium carriers
JP5645408B2 (ja) * 2006-11-16 2014-12-24 カイ ファーマシューティカルズ インコーポレーティッド 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド
US8067532B2 (en) 2007-01-19 2011-11-29 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
AU2008308679B2 (en) 2007-10-02 2015-01-29 Marina Biotech, Inc. Lipopeptides for delivery of nucleic acids
EP2229473A4 (en) 2007-12-07 2011-02-02 Steven A Goldstein IDENTIFICATION OF TOXIN LIGANDS
EP2459208B1 (en) 2009-07-29 2016-09-28 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels

Also Published As

Publication number Publication date
MX2013014249A (es) 2014-01-24
EP2717896B1 (en) 2016-08-24
CA2837445A1 (en) 2012-12-13
KR102057508B1 (ko) 2019-12-19
WO2012170955A1 (en) 2012-12-13
SI2717896T1 (sl) 2017-04-26
JP2014522414A (ja) 2014-09-04
LT2717896T (lt) 2017-02-27
SG195290A1 (en) 2013-12-30
MX337613B (es) 2016-03-10
PT2717896T (pt) 2016-12-23
AU2012267470C1 (en) 2017-09-21
AU2012267470B2 (en) 2017-06-15
EP2717896A1 (en) 2014-04-16
US8969299B2 (en) 2015-03-03
PL2717896T3 (pl) 2017-05-31
KR20140035456A (ko) 2014-03-21
ES2607986T3 (es) 2017-04-05
HUE032087T2 (en) 2017-08-28
CY1118430T1 (el) 2017-06-28
RU2013157928A (ru) 2015-07-20
SMT201700081B (it) 2017-03-08
CN103857405B (zh) 2015-12-02
CA2837445C (en) 2022-10-04
CN103857405A (zh) 2014-06-11
HRP20161566T1 (hr) 2017-02-24
RS55503B1 (sr) 2017-05-31
US20130150301A1 (en) 2013-06-13
DK2717896T3 (en) 2016-12-19
SMT201700081T1 (it) 2017-03-08
RU2612912C2 (ru) 2017-03-13
JP5982473B2 (ja) 2016-08-31

Similar Documents

Publication Publication Date Title
JP5270799B2 (ja) 副甲状腺ホルモンを低減する治療剤
JP6204369B2 (ja) カルシウム模倣薬およびその使用方法
TW202317604A (zh) 用於治療遺傳性血鐵沉積症之鐵調素模擬物
JP5982473B2 (ja) 血清リンを調節するための治療剤
AU2012267470A1 (en) Therapeutic agents for regulating serum phosphorus
WO2022052471A1 (zh) 双特异性融合多肽化合物
HK1196939B (en) Therapeutic agents for regulating serum phosphorus
CN117480176A (zh) 用于治疗遗传性血色病的铁调素模拟物

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25G Requested change of headquarter approved

Owner name: KAI PHARMACEUTICALS, INC (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]